Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Leukemia 4Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Neoplasm, Residual 1Leukemia, Myeloid, Accelerated Phase 1Graft vs Host Disease 1

Interventions

Methotrexate 5Cyclosporine 3Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Cyclophosphamide 2fludarabine phosphate 1angiotensin I (1-7) 1Sirolimus 1Nivolumab 1Methylprednisolone 1Idarubicin 1Cytarabine 1Busulfan 1Azacitidine 1Atorvastatin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Graft vs Host Disease × Idarubicin × Clear all
NCT00004878 2020-07-31

Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡